You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Aflutinib

Showing 1 - 20 of 20
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non-Small-Cell Lung Cancer Trial in Shanghai (Furmonertinib (160mg))

Recruiting
  • Non-Small-Cell Lung Cancer
  • Furmonertinib (160mg)
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Aug 2, 2022

Non Small Cell Lung Cancer Trial in Hangzhou (Furmonertinib Mesilate Tablets)

Enrolling by invitation
  • Non Small Cell Lung Cancer
  • Furmonertinib Mesilate Tablets
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, College of Medicine, Zhejiang Uni
Apr 3, 2023

NSCLC Trial (Furmonertinib)

Not yet recruiting
  • NSCLC
  • (no location specified)
Jul 17, 2022

NSCLC Trial in Shanghai (IN10018, Furmonertinib)

Recruiting
  • NSCLC
  • Shanghai, China
    Shanghai Pulmonary Hospital
Aug 8, 2023

NSCLC Trial in Changsha (Furmonertinib)

Recruiting
  • Non-Small Cell Lung Cancer
  • Changsha, Hunan, China
    Hunan Cancer hospital
May 19, 2022

NSCLC, EGFR G719X, EGFR L861Q Trial in Chongqing (Furmonertinib 160 mg, Q.D.)

Recruiting
  • Non-small Cell Lung Cancer
  • +3 more
  • Furmonertinib 160 mg, Q.D.
  • Chongqing, Chongqing, China
  • +2 more
Sep 16, 2022

NSCLC, NSCLC, Carcinoma, Bronchogenic Trial in Worldwide (Furmonertinib)

Recruiting
  • Non-Small Cell Lung Cancer
  • +14 more
  • Glendale, California
  • +12 more
Feb 2, 2023

NSCLC, NSCLC, Carcinoma, Bronchogenic Trial in United States (furmonertinib 240 mg, furmonertinib 160 mg, platinum-based chemo)

Recruiting
  • Non-Small Cell Lung Cancer
  • +13 more
  • furmonertinib 240 mg
  • +2 more
  • Yuma, Arizona
  • +37 more
Dec 14, 2022

Non-Small-Cell Lung Cancer Trial in Shanghai (Furmonertinib, Anlotinib)

Recruiting
  • Non-Small-Cell Lung Cancer
  • Shanghai, Shanghai, China
    Shanghai Chest Hospital
Oct 14, 2021

Double-dose Furmonertinib in Treatment of Slow

Not yet recruiting
  • Non Small Cell Lung Cancer
  • +3 more
  • (no location specified)
Oct 31, 2023

Lung Adenocarcinoma Trial (Furmonertinib)

Not yet recruiting
  • Lung Adenocarcinoma
  • (no location specified)
Jul 8, 2021

Adenocarcinoma of Lung Trial in Beijing (Furmonertinib)

Not yet recruiting
  • Adenocarcinoma of Lung
  • Beijing, China
    Peking University People's Hospital
Oct 3, 2021

NSCLC Trial (Furmonertinib, Furmonertinib/Pemetrexed/Carboplatin, Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab)

Recruiting
  • Non-small Cell Lung Cancer
  • Changchun, China
  • +25 more
Aug 26, 2022

Multiple Primary Lung Cancers Trial in China (furmonertinib, Placebo)

Recruiting
  • Multiple Primary Lung Cancers
  • Fuzhou, Fujian, China
  • +5 more
Oct 4, 2021

NSCLC Trial (Furmonertinib)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • (no location specified)
Aug 10, 2023

Healthy Male Volunteers Trial in Suzhou ([14]-AST2818)

Completed
  • Healthy Male Volunteers
  • Suzhou, Jiangsu, China
    First Affiliated Hospital of Soochow University
Jan 2, 2020

Healthy Male Volunteers Trial in Changsha (AST2818 Tablets)

Completed
  • Healthy Male Volunteers
  • AST2818 Tablets
  • Changsha, Hunan, China
    Hunan Provincial Tumor Hospital
Jan 2, 2020

Advanced NSCLC Trial in Beijing (Alflutinib)

Unknown status
  • Advanced NSCLC
  • Beijing, China
    cancer hospital Chinese academy of medical sciences
Jan 2, 2020

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC Trial in Beijing (Alflutinib Mesylate (AST2818) 80mg//40

Unknown status
  • Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer
  • Alflutinib Mesylate (AST2818) 80mg//40 mg+ placebo
  • +3 more
  • Beijing, China
    cancer hospital Chinese academy of medical sciences
Jan 3, 2020

NSCLC Trial (Alflutinib)

Unknown status
  • NSCLC
  • (no location specified)
Jan 2, 2020